Imunon, Inc.
IMNN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000749647
In the last 90 days, Imunon, Inc. insiders filed 0 open-market purchases and 2 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $506.1K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:14 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Feb 27, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 31, 2022 |
| Revenue | – | – | – | $500.0K | $500.0K |
| Operating expenses | $14.7M | $19.1M | $21.0M | $25.4M | $21.5M |
| Research and development | $7.78M | $11.6M | $11.3M | $11.7M | $10.6M |
| Selling, general and administrative | $6.87M | $7.49M | $9.74M | $13.7M | $10.9M |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M | -$21.0M |
| Interest expense | – | – | $197.1K | $5.03M | $569.9K |
| Income tax | – | – | -$1.28M | -$1.57M | -$1.38M |
| Net income | -$14.5M | -$18.6M | -$19.5M | -$35.9M | -$20.8M |
| EPS, basic | $-6.83 | $-1.62 | $-2.16 | $-5.03 | – |
| EPS, diluted | $-6.83 | $-1.62 | $-2.16 | – | – |
| Weighted shares, basic | 2.12M | 11.5M | 9.05M | 7.14M | – |
| Weighted shares, diluted | 2.12M | 11.5M | 9.05M | – | – |
| Margins and growth | |||||
| Operating margin | – | – | – | -4984.3% | -4201.4% |
| Net margin | – | – | – | -7179.6% | -4153.9% |
| Revenue growth, year over year | – | – | – | 0.0% | 0.0% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Feb 27, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 31, 2022 |
| Cash and equivalents | $8.78M | $5.87M | $5.84M | $11.5M | $19.6M |
| Short-term investments | – | – | $9.80M | $21.2M | $29.8M |
| Total current assets | $10.7M | $8.01M | $18.2M | $37.2M | $51.9M |
| Property, plant and equipment | $529.9K | $541.3K | $751.9K | $548.3K | $477.0K |
| Total assets | $12.3M | $9.72M | $21.9M | $44.0M | $74.0M |
| Accounts payable | – | – | $3.52M | $3.59M | $2.55M |
| Total current liabilities | $4.62M | $4.79M | $7.39M | $10.0M | $6.77M |
| Long-term debt | – | – | – | $5.96M | – |
| Total liabilities | $5.23M | $5.47M | $8.53M | $14.6M | $18.3M |
| Shareholders' equity | $7.06M | $4.24M | $13.4M | $29.3M | $55.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Feb 27, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 31, 2022 |
| Operating cash flow | -$13.9M | -$18.9M | -$19.0M | -$23.1M | -$16.2M |
| Capital expenditures | $280.6K | $29.5K | $451.8K | $267.8K | $311.6K |
| Free cash flow | -$14.2M | -$18.9M | -$19.5M | -$23.4M | -$16.5M |
| Depreciation and amortization | – | $240.0K | $248.0K | $731.6K | $702.9K |
| Stock-based compensation | $127.4K | $477.3K | $759.0K | $2.67M | $3.76M |
| Investing cash flow | -$280.6K | $9.83M | $11.0M | $8.32M | -$30.1M |
| Financing cash flow | $17.1M | $9.06M | -$3.64M | $6.72M | $54.8M |
| Net change in cash | $2.91M | $34.2K | -$11.7M | -$8.09M | $8.42M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | – | 534.6% | 751.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 12, 2026 | 6.49M | +111.3% | SEC |
| Aug 10, 2026 | 5.61M | +156.0% | SEC |
| May 11, 2026 | 4.20M | −71.3% | SEC |
| Mar 30, 2026 | 3.92M | −73.2% | SEC |
| Nov 10, 2025 | 3.07M | −78.8% | SEC |
| Aug 1, 2025 | 2.19M | −84.8% | SEC |
| May 9, 2025 | 14.6M | +55.5% | SEC |
| Feb 21, 2025 | 14.6M | +55.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q1 2022 and 1-for-13 in Q3 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.